Dr Constantine Alifrangis

Tel: 0203 447 9088
Email: constantine.alifrangis1@nhs.net

University College Hospital

Urological Cancers

Professional background

Dr Costi Alifrangis is a consultant medical oncologist specialising in the treatment of urological cancers including prostate, bladder, and testicular cancer.

He obtained his medical degree at Guys’ Kings and St Thomas’ Medical school where he was awarded the university gold medal for medicine. He undertook postgraduate medical training in London and Brighton and trained in oncology on the Imperial College medical oncology rotation.

As an academic clinical fellow at Hammersmith Hospital he worked on hormone resistance in prostate cancer and subsequently secured a Wellcome Trust fellowship to undertake a PhD at the Wellcome Trust Sanger Institute and University of Cambridge.

Dr Alifrangis’ research has focused on the intersection of genomics and therapeutics in the area of drug resistance including personalized approaches to cancer treatment. He has published original research in journals such as the Journal of Clinical Oncology and was awarded the Sylvia Lawler Prize by the oncology section of the Royal Society of Medicine. His research has been presented at international conferences and has led to a novel biomarker which he plans to take forward in clinical trials to benefit patients at UCLH. He also has an interest in understanding the experiences of cancer patients and in post treatment health issues in cancer survivors.

Dr Alifrangis was appointed consultant medical oncologist at UCLH in 2016.

Research interests

Drug resistance


  • Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.
    Brammeld J, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, Stebbings L, Beal K, Stratton MR, Saez-Rodriguez J, Garnett M, Montagut C, Iorio F, McDermott U.
    Genome Res. 2017 Feb 8. pii: gr.213546.116. doi: 10.1101/gr.213546.116.
    PMID 28179366
  • Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.
    Alifrangis C, Thornton A, Fotopoulou C, Krell J, Gabra H.
    Gynecol Oncol Rep. 2016 Nov 6;18:42-44.
  • Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention.
    Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G.
    Oncogene. 2017 Feb 16;36(7):877-884. doi: 10.1038/onc.2016.253. Review.
  • BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
    Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ.
    Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E536-45. doi: 10.1073/pnas.1418163112.
  •  BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.
    Ranzani M, Alifrangis C, Perna D, Dutton-Regester K, Pritchard A, Wong K, Rashid M, Robles-Espinoza CD, Hayward NK, McDermott U, Garnett M, Adams DJ.
    Pigment Cell Melanoma Res. 2015 Jan;28(1):117-9. doi: 10.1111/pcmr.12316. No abstract available.
  • Reading between the lines; understanding drug response in the post genomic era.
    Alifrangis CC, McDermott U.
    Mol Oncol. 2014 Sep 12;8(6):1112-9. doi: 10.1016/j.molonc.2014.05.014. Review.
  • The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.
    Stebbing J, Harding V, Urch CE, Kaier T, Schofield G, Flook M, Alifrangis C, Young AM, Shaw JA, Coombes RC, Krell J.
    Future Oncol. 2014 Dec;10(16):2555-60. doi: 10.2217/FON.14.107.
  • Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010.
    Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW, Coleman RE, Seckl MJ.
    J Reprod Med. 2014 Jan-Feb;59(1-2):7-12.
  • Inactivating CUX1 mutations promote tumorigenesis.
    Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium., Green AR, Massie CE, Nangalia J, Lempidaki S, Döhner H, Döhner K, Bray SJ, McDermott U, Papaemmanuil E, Campbell PJ, Adams DJ.
    Nat Genet. 2014 Jan;46(1):33-8. doi: 10.1038/ng.2846.
  • EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
    Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ.
    J Clin Oncol. 2013 Jan 10;31(2):280-6. doi: 10.1200/JCO.2012.43.1817.
  • A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
    Palmieri C, Alifrangis C, Shipway D, Tat T, Watson V, Mackie D, Emson M, Coombes RC.
    Oncologist. 2012;17(11):1429-e47. doi: 10.1634/theoncologist.2012-0161.
  • Role of thoracotomy and metastatectomy in gestational trophoblastic neoplasia: a single center experience.
    Alifrangis C, Wilkinson MJ, Stefanou DC, Virk JS, Anderson J, Seckl MJ.
    J Reprod Med. 2012 Jul-Aug;57(7-8):350-8.
  • Shark cartilage: has the popularisation of science failed?
    Alifrangis C, Stebbing J.
    Lancet Oncol. 2012 Jan;13(1):22. doi: 10.1016/S1470-2045(11)70425-9. No abstract available.
  • New drugs for prostate cancer. Alifrangis C, O'Hanlon-Brown C, Tuthill M, Waxman J. BJU Int. 2012 Jun;109(12):1801-6. doi: 10.1111/j.1464-410X.2011.10570.x. Review.
  • An unusual gum lesion with a positive pregnancy test. Alifrangis C, Evans R, Williams J, Seckl MJ. BMJ. 2011 Aug 11;343:d5009. doi: 10.1136/bmj.d5009. No abstract available.
  • The experiences of cancer patients. Alifrangis C, Koizia L, Rozario A, Rodney S, Harrington M, Somerville C, Peplow T, Waxman J. QJM. 2011 Dec;104(12):1075-81. doi: 10.1093/qjmed/hcr129.
  • The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution? Alifrangis C, Krell J, Stebbing J. Eur J Cancer. 2011 Jun;47(9):1285-6. doi: 10.1016/j.ejca.2011.04.002. No abstract available.
    PMID: 21550231
  • Anti Ma2-associated myeloradiculopathy: expanding the phenotype of anti-Ma2 associated paraneoplastic syndromes. Murphy SM, Khan U, Alifrangis C, Hazell S, Hrouda D, Blake J, Ball J, Gabriel C, Markarian P, Rees J, Karim A, Seckl MJ, Lunn MP, Reilly MM. J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):232-3. doi: 10.1136/jnnp.2010.223271. No abstract available.
  • Genetics of gestational trophoblastic neoplasia: an update for the clinician. Alifrangis C, Seckl MJ. Future Oncol. 2010 Dec;6(12):1915-23. doi: 10.2217/fon.10.153. Review.
  • Poor reception? Alifrangis C, Harcourt JP, Gojis O, Palmieri C. Lancet. 2009 Sep 12;374(9693):948. doi: 10.1016/S0140-6736(09)61120-X. No abstract available.

GMC/GDC number: 6120950